BioCentury
ARTICLE | Finance

Extra crisp

Why Versant Ventures thinks there's room for another CRISPR-Cas9 play

April 28, 2014 7:00 AM UTC

Versant Ventures is adding another horse to the CRISPR-Cas9 therapeutics race with last week's $25 million series A round for CRISPR Therapeutics.

Versant was the sole investor in CRISPR, which is developing gene editing therapies for serious genetic diseases...